Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.

Autor: Brøndum, Line¹ line@oncology.au.dk, Alsner, Jan¹, Sørensen, Brita Singers¹, Maare, Christian², Johansen, Jørgen³, Primdahl, Hanne⁴, Evensen, Jan Folkvard⁵, Kristensen, Claus Andrup⁶, Andersen, Lisbeth Juhler⁷, Overgaard, Jens¹, Eriksen, Jesper Grau¹

Publikováno v: Acta Oncologica. Supplement. 2018, Vol. 57 Issue 9, p1159-1164. 6p.

Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial

Autor: Claus Kristensen, Line Brøndum, Jan F. Evensen, Jens Overgaard, C. Maare, Jan Alsner, Jørgen Johansen, Brita Singers Sørensen, Jesper Grau Eriksen, Lisbeth Juhler Andersen, Hanne Primdahl

Publikováno v: Brøndum, L, Alsner, J, Sørensen, B S, Maare, C, Johansen, J, Primdahl, H, Evensen, J F, Kristensen, C A, Andersen, L J, Overgaard, J & Eriksen, J G 2018, ' Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial ', Acta Oncologica, vol. 57, no. 9, pp. 1159-1164 . https://doi.org/10.1080/0284186X.2018.1464664
Brøndum, L, Alsner, J, Sørensen, B S, Maare, C, Johansen, J, Primdahl, H, Evensen, J F, Kristensen, C A, Andersen, L J, Overgaard, J & Eriksen, J G 2018, ' Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab : results from the DAHANCA 19 trial ', Acta Oncologica, vol. 57, no. 9, pp. 1159-1164 . https://doi.org/10.1080/0284186X.2018.1464664

Purpose: To study the associations between development of moderate to severe skin rash, clinical outcome, and single nucleotide polymorphisms (SNPs) in candidate genes in head and neck cancer patients from the DAHANCA 19 trial receiving the EGFR-inhi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba1e936eb750b6dde160b2d983dbcb95

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.

Autor: Rivera, Fernando¹ oncrhf@humv.es, Vega-Villegas, Ma Eugenia¹, Lopez-Brea, Marta F.¹, Marquez, Raul¹

Publikováno v: Acta Oncologica. Jan2008, Vol. 47 Issue 1, p9-19. 11p. 4 Charts.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Zalutumumab in head and neck cancer

Autor: T.M. Richards, Christopher M. Nutting, Ulrike Schick, Kevin J. Harrington, Dorothy M. Gujral

Publikováno v: Expert Opinion on Biological Therapy. 12:119-125

Over 90% of head and neck cancers overexpress EGFR. This correlates with advanced disease stage and worse prognosis. Strategies to inhibit the EGFR pathway have been developed over the last decade. Zalutumumab is a recent high-affinity completely hum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c7937a538caea80c7b65bf61e0c2e9
https://doi.org/10.1517/14712598.2012.643864